Hot News: AIDU Biotech's Fisetin Demonstrates Significant Antioxidant Effects in Zebrafish Clinical Trial
- Sep 22, 2025-
Shanghai AIDU Biotechnology Co., Ltd. is proud to announce the successful completion of a zebrafish clinical trial evaluating the antioxidant properties of its fisetin product. The study confirms fisetin’s efficacy in reducing oxidative stress under experimental conditions.
Key Findings:
Antioxidant Performance: Compared to the blank control group, fisetin reduced reactive oxygen species (ROS) fluorescence intensity by 16.95% (P < 0.05), demonstrating statistically significant antioxidant effects.
Safety Profile: The maximum safe concentration (MTC) was determined to be 200 μg/mL, with no adverse effects observed at this dosage.
Methodology: The study utilized wild AB strain zebrafish (3 days post-fertilization) and adhered to national standards (GB/T 39649-2020, GB/T 13267-1991) for experimental rigor.
Scientific Implications: Fisetin's ability to mitigate ROS-induced oxidative damage highlights its potential as a bioactive compound for health applications. The results align with the growing demand for natural antioxidants in functional foods and nutraceuticals.
"This study underscores our commitment to evidence-based research and innovation in biotechnology," said a spokesperson from AIDU Biotech. "We look forward to further exploring fisetin's benefits."
Note: Results are based on tested samples and intended for research purposes.
Related Products
